Welcome to LookChem.com Sign In|Join Free

CAS

  • or

179055-20-0

Post Buying Request

179055-20-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

179055-20-0 Usage

Description

[4-(1-Methyl-1H-pyrazol-3-yl)phenyl]methanol is a chemical compound characterized by its molecular formula C12H12N2O. It is a phenylmethanol derivative that features a pyrazole ring and a methyl group. [4-(1-Methyl-1H-pyrazol-3-yl)phenyl]methanol holds promise in pharmaceutical research and development due to its unique structural attributes and potential pharmacological properties. It is recognized for its capacity to serve as a building block in the synthesis of a variety of biologically active compounds, making it a valuable asset in medicinal chemistry for the exploration of novel drug candidates.

Uses

Used in Pharmaceutical Research and Development:
[4-(1-Methyl-1H-pyrazol-3-yl)phenyl]methanol is utilized as a key intermediate in the synthesis of biologically active compounds, contributing to the development of new pharmaceuticals. Its unique structure allows for the creation of diverse molecules with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, [4-(1-Methyl-1H-pyrazol-3-yl)phenyl]methanol is employed as a structural component in the design and discovery of new drug candidates. Its presence in compounds can influence pharmacokinetic and pharmacodynamic properties, thereby enhancing the effectiveness and safety profiles of potential medications.
Used in Drug Synthesis:
[4-(1-Methyl-1H-pyrazol-3-yl)phenyl]methanol is used as a building block in drug synthesis for the creation of molecules with specific biological activities. Its incorporation into various chemical frameworks can lead to the discovery of compounds with improved therapeutic potential.
Note: Since the provided materials do not specify particular industries or reasons for the applications of [4-(1-Methyl-1H-pyrazol-3-yl)phenyl]methanol, the uses listed are generalized to the pharmaceutical and medicinal chemistry fields. Further research and studies are necessary to identify specific applications and benefits within the pharmaceutical industry.

Check Digit Verification of cas no

The CAS Registry Mumber 179055-20-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,0,5 and 5 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 179055-20:
(8*1)+(7*7)+(6*9)+(5*0)+(4*5)+(3*5)+(2*2)+(1*0)=150
150 % 10 = 0
So 179055-20-0 is a valid CAS Registry Number.
InChI:InChI=1/C11H12N2O/c1-13-7-6-11(12-13)10-4-2-9(8-14)3-5-10/h2-7,14H,8H2,1H3

179055-20-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name [4-(1-methylpyrazol-3-yl)phenyl]methanol

1.2 Other means of identification

Product number -
Other names (4-(1-Methyl-1H-pyrazol-3-yl)phenyl)methanol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:179055-20-0 SDS

179055-20-0Relevant articles and documents

NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS

-

Paragraph 526; 572, (2021/12/28)

The present disclosure provides compounds having Formula (I): (I) and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R6, R6', R7, and R7' are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.

Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor with Weak Agonist Activity and Diverse Modulatory Profiles

Dallagnol, Juliana C. C.,Khajehali, Elham,Van Der Westhuizen, Emma T.,J?rg, Manuela,Valant, Celine,Gon?alves, Alan G.,Capuano, Ben,Christopoulos, Arthur,Scammells, Peter J.

, p. 2875 - 2894 (2018/04/23)

Targeting allosteric sites at M1 muscarinic acetylcholine receptors is a promising strategy for the treatment of Alzheimer's disease. Positive allosteric modulators not only may potentiate binding and/or signaling of the endogenous agonist acetylcholine (ACh) but also may possess direct agonist activity (thus referred to as PAM-agonists). Recent studies suggest that PAM-agonists with robust intrinsic efficacy are more likely to produce adverse effects in vivo. Herein we present the synthesis and pharmacological evaluation of a series of pyrrole-3-carboxamides with a diverse range of allosteric profiles. We proposed structural modifications at top, core, or pendant moieties of a prototypical molecule. Although generally there was a correlation between the degree of agonist activity and the modulatory potency of the PAMs, some derivatives displayed weak intrinsic efficacy yet maintained strong allosteric modulation. We also identified molecules with the ability to potentiate mainly the affinity or both affinity and efficacy of ACh.

ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE

-

Paragraph 0426, (2015/11/10)

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. (I) wherein each symbol is as described in the specification, or a salt thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 179055-20-0